IL22 and inflammatory bowel disease: Studies have shown that selective agonists for activation of the A2A receptor reduced tissue damage in various animal models of IBD.44, 50 Our results provide new insights into how alterations in purine metabolism in response to tissue damage modulate the pathophysiology of IBD, that is, through interaction with the ILC3‐IL‐22 pathway.